Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | APP | P05067 | 4/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8330079 | 1.00 | ATM (0.70) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL7247825 | 0.89 | ATM (0.67) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL7247824 | 0.89 | ATM (0.67) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL15159951 | 0.88 | ATM (0.73) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL271855 | 0.87 | ATM (0.71) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL4781275 | 0.87 | ATM (0.71) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL1529562 | 0.87 | ATM (0.71) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL257912 | 0.87 | ATM (0.71) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL8370126 | 0.87 | ATM (0.71) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL5755466 | 0.86 | ATM (0.53) | ATMAPPCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | disclosed |
| EP-1401821-A4 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK CORP (KR) | 2006-05-31 | — | — | EP | disclosed |
| EP-1401821-A1 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK Corporation (KR) | 2004-03-31 | — | — | EP | disclosed |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | disclosed |
| WO-2002100848-A1 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK CORPORATION (KR) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SIGMAR1, TAAR1, OPRL1 | ATM 3190/4885APP 920/4885CTSS 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.